Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor

Oncogene

Volumn 30, Issue 2, 2011, Pages 190-200

  Dwyer, J ^a,b   Le Guelte, A ^a,b   Galan Moya, E M ^a,b   Sumbal, M ^a,b   Carlotti, A ^c   Douguet, L ^a,b   Gutkind, J S ^d   Grange, P A ^e   Dupin, N ^c,e   Gavard, J ^a,b  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c Universite Paris Descartes ^*  (France)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

cell junctions; kaposi sarcoma; permeability; PI(3)K; rac; VE cadherin

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; RAC PROTEIN; SMALL INTERFERING RNA; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL CONTACT; CELL JUNCTION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN TISSUE; IMMUNE DEFICIENCY; KAPOSI SARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANDROSTADIENES; ANIMALS; ANTIGENS, CD; CADHERINS; CAPILLARY PERMEABILITY; CELL LINE; CHROMONES; CINNAMATES; ENDOTHELIAL CELLS; ENZYME INHIBITORS; FEMALE; FURANS; HERPESVIRUS 8, HUMAN; HUMANS; INDOLES; INTERCELLULAR JUNCTIONS; MICE; MICE, NUDE; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIDINES; PYRIMIDINES; QUINOXALINES; RECEPTORS, CHEMOKINE; RNA, SMALL INTERFERING; SARCOMA, KAPOSI; SKIN; SKIN NEOPLASMS; SULFONAMIDES; THIAZOLIDINEDIONES;

HUMAN HERPESVIRUS 8;

EID: 78651409313     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.411     Document Type: Article

References (38)

1. Ascherl G, Hohenadl C, Schatz O, Shumay E, Bogner J, Eckhart L et al (1999). Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy. Blood 93: 4232-4241.
2. 0s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391: 86-89. (Pubitemid 28079220)
3. Barber DF, Bartolome A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C et al. (2005). PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 11: 933-935.
4. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J et al. (2005). Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11: 936-943.
5. Cesarman E, Mesri EA. (2007). Kaposi sarcoma-associated herpes-virus and other viruses in human lymphomagenesis. Curr Top Microbiol Immunol 312: 263-287.
6. Chaisuparat R, Hu J, Jham BC, Knight ZA, Shokat KM, Montaner S. (2008). Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res 68: 8361-8368.
7. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM et al. (1994). Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865-1869.
8. Chiou CJ, Poole LJ, Kim PS, Ciufo DM, Cannon JS, Rhys CM et al. (2002). Patterns of gene expression and a transactivation function exhibited by the vGCR (ORF74) chemokine receptor protein of Kaposi's sarcoma-associated herpesvirus. J Virol 76: 3421-3439.
9. Dejana E. (2004). Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 5: 261-270.
10. 0s disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 96: 4546-4551.
11. Dupin N, Grange PA. (2006). Looking for the target cell of Kaposi's sarcoma-associated herpesvirus. J Invest Dermatol 126: 545-547.
12. Gavard J, Gutkind JS. (2006). VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8: 1223-1234.
13. Gavard J, Hou X, Qu Y, Masedunskas A, Martin D, Weigert R et al. (2009). A role for a CXCR2/phosphatidylinositol 3-kinase gamma signaling axis in acute and chronic vascular permeability. Mol Cell Biol 29: 2469-2480.
14. Gavard J, Lambert M, Grosheva I, Marthiens V, Irinopoulou T, Riou JF et al. (2004). Lamellipodium extension and cadherin adhesion: two cell responses to cadherin activation relying on distinct signalling pathways. J Cell Sci 117: 257-270.
15. Gavard J, Patel V, Gutkind JS. (2008). Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 14: 25-36.
16. Grisotto MG, Garin A, Martin AP, Jensen KK, Chan P, Sealfon SC et al. (2006). The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J Clin Invest 116: 1264-1273.
17. Grundhoff A, Ganem D. (2004). Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 113: 124-136.
18. 0s sarcoma virus vGPCR-induced direct and paracrine neoplasia. Oncogene 27: 1844-1852.
19. Maurer T, Ponte M, Leslie K. (2007). HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 357: 1352-1353.
20. Mitsuyasu RT. (2000). Update on the pathogenesis and treatment of Kaposi sarcoma. Curr Opin Oncol 12: 174-180.
21. Monini P, Sgadari C, Grosso MG, Bellino S, Di Biagio A, Toschi E et al. (2009). Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 23: 534-538.
22. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y et al. (2003). Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3: 23-36.
23. Montaner S, Sodhi A, Pece S, Mesri EA, Gutkind JS. (2001). The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res 61: 2641-2648.
24. Montaner S, Sodhi A, Ramsdell AK, Martin D, Hu J, Sawai ET et al. (2006). The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res 66: 168-174. (Pubitemid 43166022)
25. Montaner S, Sodhi A, Servitja JM, Ramsdell AK, Barac A, Sawai ET et al. (2004). The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood 104: 2903-2911.
26. Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, Duran EM et al. (2007). In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 11: 245-258. (Pubitemid 46357638)
27. Oksenhendler E, Boulanger E, Galicier L, Du MQ, Dupin N, Diss TC et al. (2002). High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 99: 2331-2336.
28. Orenstein JM, Alkan S, Blauvelt A, Jeang KT, Weinstein MD, Ganem D et al. (1997). Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy. AIDS 11: F35-F45.
29. Qian LW, Greene W, Ye F, Gao SJ. (2008). Kaposi's sarcoma-associated herpesvirus disrupts adherens junctions and increases endothelial permeability by inducing degradation of VE-cadherin. J Virol 82: 11902-11912.
30. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S et al. (2002). HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8: 225-232.
31. Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA et al. (2006). The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 10: 133-143.
32. Sodhi A, Montaner S, Gutkind JS. (2004a). Viral hijacking of G-protein-coupled-receptor signalling networks. Nat Rev Mol Cell Biol 5: 998-1012.
33. Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, Sausville EA et al. (2004b). Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci USA 101: 4821-4826.
34. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA et al. (2000). The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 60: 4873-4880.
35. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G et al. (2005). Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352: 1317-1323.
36. Szajerka T, Jablecki J. (2007). Kaposi's sarcoma revisited. AIDS Rev 9: 230-236.
37. Taddei A, Giampietro C, Conti A, Orsenigo F, Breviario F, Pirazzoli V et al. (2008). Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat Cell Biol 10: 923-934.
38. Weis SM, Cheresh DA. (2005). Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437: 497-504.